Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
Advanced
Cancer
Clinical trial
First-in-class
First-in-human
LNA-i-miR-221
Non-coding RNA therapeutics
Phase 1
RNA therapeutics
Refractory
miR-221
miRNA
miRNA therapeutics
microRNA
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
26 06 2023
26 06 2023
Historique:
received:
25
12
2022
accepted:
16
06
2023
medline:
28
6
2023
pubmed:
27
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
We developed a 13-mer locked nucleic acid (LNA) inhibitor of miR-221 (LNA-i-miR-221) with a full phosphorothioate (PS)-modified backbone. This agent downregulated miR-221, demonstrated anti-tumor activity against human xenografts in mice, and favorable toxicokinetics in rats and monkeys. Allometric interspecies scaling allowed us to define the first-in-class LNA-i-miR-221 safe starting dose for the clinical translation. In this first-in-human, open-label, dose-escalation phase 1 trial, we enrolled progressive cancer patients (aged ≥ 18 years) with ECOG 0-2 into 5 cohorts. The treatment cycle was based on a 30-min IV infusion of LNA-i-miR-221 on 4 consecutive days. Three patients within the first cohort were treated with 2 cycles (8 infusions), while 14 patients were treated with a single course (4 infusions); all patients were evaluated for phase 1 primary endpoint. The study was approved by the Ethics Committee and Regulatory Authorities (EudraCT 2017-002615-33). Seventeen patients received the investigational treatment, and 16 were evaluable for response. LNA-i-miR-221 was well tolerated, with no grade 3-4 toxicity, and the MTD was not reached. We recorded stable disease (SD) in 8 (50.0%) patients and partial response (PR) in 1 (6.3%) colorectal cancer case (total SD + PR: 56.3%). Pharmacokinetics indicated non-linear drug concentration increase across the dose range. Pharmacodynamics demonstrated concentration-dependent downregulation of miR-221 and upregulation of its CDKN1B/p27 and PTEN canonical targets. Five mg/kg was defined as the recommended phase II dose. The excellent safety profile, the promising bio-modulator, and the anti-tumor activity offer the rationale for further clinical investigation of LNA-i-miR-221 (ClinTrials.Gov: NCT04811898).
Sections du résumé
BACKGROUND
We developed a 13-mer locked nucleic acid (LNA) inhibitor of miR-221 (LNA-i-miR-221) with a full phosphorothioate (PS)-modified backbone. This agent downregulated miR-221, demonstrated anti-tumor activity against human xenografts in mice, and favorable toxicokinetics in rats and monkeys. Allometric interspecies scaling allowed us to define the first-in-class LNA-i-miR-221 safe starting dose for the clinical translation.
METHODS
In this first-in-human, open-label, dose-escalation phase 1 trial, we enrolled progressive cancer patients (aged ≥ 18 years) with ECOG 0-2 into 5 cohorts. The treatment cycle was based on a 30-min IV infusion of LNA-i-miR-221 on 4 consecutive days. Three patients within the first cohort were treated with 2 cycles (8 infusions), while 14 patients were treated with a single course (4 infusions); all patients were evaluated for phase 1 primary endpoint. The study was approved by the Ethics Committee and Regulatory Authorities (EudraCT 2017-002615-33).
RESULTS
Seventeen patients received the investigational treatment, and 16 were evaluable for response. LNA-i-miR-221 was well tolerated, with no grade 3-4 toxicity, and the MTD was not reached. We recorded stable disease (SD) in 8 (50.0%) patients and partial response (PR) in 1 (6.3%) colorectal cancer case (total SD + PR: 56.3%). Pharmacokinetics indicated non-linear drug concentration increase across the dose range. Pharmacodynamics demonstrated concentration-dependent downregulation of miR-221 and upregulation of its CDKN1B/p27 and PTEN canonical targets. Five mg/kg was defined as the recommended phase II dose.
CONCLUSIONS
The excellent safety profile, the promising bio-modulator, and the anti-tumor activity offer the rationale for further clinical investigation of LNA-i-miR-221 (ClinTrials.Gov: NCT04811898).
Identifiants
pubmed: 37365583
doi: 10.1186/s13045-023-01468-8
pii: 10.1186/s13045-023-01468-8
pmc: PMC10294514
doi:
Substances chimiques
locked nucleic acid
0
MicroRNAs
0
MIRN221 microRNA, human
0
MIRN221 microRNA, rat
0
Oligonucleotides
0
Banques de données
ClinicalTrials.gov
['NCT04811898']
EudraCT
['2017-002615-33']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
68Informations de copyright
© 2023. The Author(s).
Références
Mol Ther Nucleic Acids. 2016 Jun 21;5(6):
pubmed: 27327137
Cancers (Basel). 2019 Dec 19;12(1):
pubmed: 31861748
Trends Genet. 2022 Jun;38(6):613-626
pubmed: 35303998
Clin Cancer Res. 2016 Mar 1;22(5):1222-33
pubmed: 26527748
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
J Pharm Biomed Anal. 2020 Sep 5;188:113451
pubmed: 32659676
Nat Rev Drug Discov. 2020 Oct;19(10):673-694
pubmed: 32782413
Oncotarget. 2013 Feb;4(2):242-55
pubmed: 23479461
Invest New Drugs. 2017 Apr;35(2):180-188
pubmed: 27917453
Annu Rev Pathol. 2014;9:287-314
pubmed: 24079833
PLoS One. 2014 Feb 21;9(2):e89659
pubmed: 24586944
N Engl J Med. 2021 Apr 22;384(16):1576-1577
pubmed: 33596348
J Clin Med. 2020 Jun 26;9(6):
pubmed: 32604776
Nat Rev Cancer. 2021 Jan;21(1):22-36
pubmed: 33082563
Mol Ther Nucleic Acids. 2022 Feb 11;27:1191-1224
pubmed: 35282417
Nat Biotechnol. 2017 Mar;35(3):222-229
pubmed: 28244992
EBioMedicine. 2016 Oct;12:34-42
pubmed: 27720213
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
J Invest Dermatol. 2019 May;139(5):1073-1081
pubmed: 30472058
Mol Ther Nucleic Acids. 2020 Jun 5;20:73-85
pubmed: 32146420
N Engl J Med. 2013 May 2;368(18):1685-94
pubmed: 23534542